



## An early-life diet containing large phospholipid-coated lipid globules programmes later-life postabsorptive lipid trafficking in high-fat diet- but not in low-fat diet-fed mice

Onne A. H. O. Ronda<sup>1</sup>, Bert J. M. van de Heijning<sup>2</sup>, Ingrid A. Martini<sup>3</sup>, Martijn Koehorst<sup>3</sup>, Rick Havinga<sup>1</sup>, Angelika Jurdzinski<sup>1</sup>, Vincent W. Bloks<sup>1</sup>, Theo H. van Dijk<sup>3</sup>, Eline M. van der Beek<sup>1,2</sup>, Folkert Kuipers<sup>1,3</sup> and Henkjan J. Verkade<sup>1\*</sup>

<sup>1</sup>Department of Pediatrics, Laboratory Medicine, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands

<sup>2</sup>Danone Nutricia Research, Early Life Nutrition, Uppsalalaan 12, 3584 CT Utrecht, The Netherlands

<sup>3</sup>Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands

(Submitted 25 November 2019 – Final revision received 8 June 2020 – Accepted 26 June 2020)

### Abstract

Feeding mice in early life a diet containing an experimental infant milk formula (Nuturis®; eIMF), with a lipid structure similar to human milk, transiently lowered body weight (BW) and fat mass gain upon Western-style diet later in life, when compared with mice fed diets based on control IMF (cIMF). We tested the hypothesis that early-life eIMF feeding alters the absorption or the postabsorptive trafficking of dietary lipids in later life. Male C57BL/6JOLA<sup>Hsd</sup> mice were fed eIMF/cIMF from postnatal day 16–42, followed by low- (LFD, American Institute of Nutrition (AIN)-93 G, 7 wt% fat) or high-fat diet (HFD, D12451, 24 wt% fat) until day 63–70. Lipid absorption rate and tissue concentrations were determined after intragastric administration of stable isotope (<sup>2</sup>H or <sup>13</sup>C) labelled lipids in separate groups. Lipid enrichments in plasma and tissues were analysed using GC-MS. The rate of triolein absorption was similar between eIMF and cIMF fed LFD: 3.2 (SD 1.8) and 3.9 (SD 2.1) and HFD: 2.6 (SD 1.7) and 3.8 (SD 3.0) % dose/ml per h. Postabsorptive lipid trafficking, that is, concentrations of absorbed lipids in tissues, was similar in the eIMF and cIMF groups after LFD. Tissue levels of absorbed TAG after HFD feeding were lower in heart (–42%) and liver (–46%), and higher in muscle (+81%, all  $P < 0.05$ ) in eIMF-fed mice. In conclusion, early-life IMF diet affected postabsorptive trafficking of absorbed lipids after HFD, but not LFD. Changes in postabsorptive lipid trafficking could underlie the observed lower BW and body fat accumulation in later life upon a persistent long-term obesogenic challenge.

**Key words:** Metabolic programming; Infant nutrition; Dietary lipids; Lipid structure; Milk fat globule membrane; Obesity prevention

Breast-feeding *vs.* infant milk formula (IMF) feeding is epidemiologically associated with a lower incidence of childhood, adolescent and adulthood obesity<sup>(1,2)</sup>. The difference in obesity incidence could, in part, be due to (metabolic) ‘programming’, a stimulus/insult during a critical or sensitive window of development, with long-term (even lifelong) effects on an organism<sup>(3–5)</sup>. Distinct compositional or physicochemical differences between human milk and formulae have been suggested to underlie the observed long-term differences in body weight (BW) and fat mass gain<sup>(6,7)</sup>. A major difference between human milk and IMF, potentially relevant for metabolic programming, concerns the emulsification characteristics of the (milk) fat. Fat provides the largest fraction

(50%) of energy in human milk and also supplies essential building blocks for growth and development<sup>(8)</sup>. Fat in human milk is present as an emulsion of fat (globules) in water. In native human milk, the fat globules are emulsified by the milk fat globule membrane (MFGM)<sup>(9)</sup>. The MFGM consists of a unique tri-layer phospholipid membrane<sup>(9)</sup>, extensively reviewed by Patton & Keenan<sup>(10)</sup>. Human milk fat globules have a mode diameter (the diameter most abundant by particle volume) of approximately 3–5 μm<sup>(8,10)</sup>. The physicochemical structure of milk fat globules (the MFGM, i.e. its phospholipid membrane and large diameter) modulates gastrointestinal lipolysis, postprandial lipaemia and, to some extent, the postabsorptive metabolism of absorbed fats<sup>(7,11,12)</sup>.

**Abbreviations:** BW, body weight; cIMF, control infant milk formula; CM, chylomicron; eIMF, experimental infant milk formula; FC, free cholesterol; HFD, high-fat diet; IMF, infant milk formula; LFD, low-fat diet; LPL, lipoprotein lipase; MFGM, milk fat globule membrane; PN, postnatal.

\* **Corresponding author:** Henkjan J. Verkade, fax +31-50-361 1746, email [h.j.verkade@umcg.nl](mailto:h.j.verkade@umcg.nl)

Infant formulae contain adequate amounts of essential nutritional components for growth and development<sup>(13)</sup>. Nevertheless, the biochemical and physicochemical composition of infant formulae has continued to be an area of research and innovation, primarily aimed to further ‘humanise’ infant formulae<sup>(13)</sup>. Most infant formulae contain lipids from vegetable sources, which are primarily emulsified by protein aggregates, do not contain MFGM and have much smaller fat globules with a mode diameter of 0.2 µm in diameter<sup>(14,15)</sup>. When the physicochemical structure of MFGM is mimicked in an experimental IMF (eIMF) and fed to mice in early life, these mice gain less BW and fat mass when challenged with a Western-style diet later in life, when compared with mice fed a control IMF (cIMF)<sup>(15–18)</sup>. The eIMF is a concept IMF with large, phospholipid-coated lipid droplets (mode diameter 3–5 µm; Nuturis<sup>®</sup>)<sup>(9)</sup>. BW gain is not different from controls during early-life IMF feeding<sup>(18)</sup>. Upon prolonged exposure to a Western-style diet, the beneficial effects of eIMF on BW and fat mass gain diminish over time, indicating the limits of early-life programming in a challenging later-life environment<sup>(18)</sup>. The transient nature implies that the capability to gain BW and fat mass is not permanently affected. Thus, the lower BW and fat mass gain may be due to a less positive energy balance, instead of permanently impaired capacity to store lipids *per se*.

The beneficial effects of MFGM-enriched infant formulae on BW and fat mass gain are only observed when adding MFGM as a coating to IMF containing large lipid globules and not upon adding MFGM as a coating to IMF containing small lipid globules<sup>(15)</sup>. The beneficial effects on BW and fat mass gain are also not found upon adding phospholipids in their free form<sup>(19)</sup>. Distinct physicochemical differences may thus underlie the observed long-term effects on BW and fat mass gain. In rats, gavage of human milk, *v.* formula, leads to a more rapid chylomicron (CM) production<sup>(20)</sup>. Breastfed infants, *v.* formula-fed infants, have a higher TAG:apo B48 ratio, suggesting that the CM are larger in volume and carry a larger fat load in these infants<sup>(6)</sup>. Thus, differences in physicochemical structure may result in different rates of lipid uptake: lipids from human milk could be more rapidly absorbed than infant formulae. In adulthood, the rate of fat absorption is related to the postabsorptive trafficking and the metabolic ‘fate’; rapid absorption leads to higher  $\beta$ -oxidation rates at the expense of lipid storage<sup>(21)</sup>. This could imply that, in adulthood, rapid fat absorption leads to rapid lipoprotein lipase (LPL)-mediated hydrolysis and tissue uptake of CM-TAG. Likely, CM particle diameter will be larger upon a high rate of fat absorption compared with a low rate of fat absorption<sup>(21)</sup>.

Based on these considerations, we hypothesise that early-life eIMF *v.* cIMF feeding differentially programmes the rate of absorption and/or postabsorptive trafficking of fat in later life<sup>(6,12,21,22)</sup>. In obese *v.* control subjects, the activity of the rate-limiting enzyme for the tissue uptake and storage of absorbed lipids (lipoprotein lipase) in adipose tissue is higher<sup>(23)</sup>. It is not well understood in which external factors influence the tissue uptake and storage of absorbed lipids, when the dietary lipids have identical properties. We speculate that these factors may be the diet (i.e. a high- or low-fat diet (HFD or LFD, respectively)), the amount of energy intake or the adiposity

(i.e. the amount of adipose tissue). We incorporated both aspects into our experimental design. In this study, we tested the hypothesis in HFD (obesogenic) and LFD (non-obesogenic) conditions. Here, we consider an obesogenic condition one wherein excess BW and fat mass accumulates or is maintained. In previous works, we noted that BW and adiposity were similar between eIMF and cIMF at postnatal (PN) day 70, after which eIMF-fed mice gained less BW and fat mass<sup>(18)</sup>. To disentangle the possible immediate effects of the IMF diets, the effect of BW or fat mass, and the programming effect, we chose a time point immediately prior to the observed divergence in BW and fat mass: PN day 63–70. We tested the hypothesis by quantifying the rate of fat absorption and the postabsorptive lipid trafficking in mice that were fed eIMF or cIMF in early life, followed by either a LFD or a HFD into adulthood.

## Materials and methods

### Animals and study design

Experimental procedures were approved by an external independent animal experiment committee (CCD, Central Animal Experiments Committee, The Netherlands), after positive advice by the Committee for Animal Experimentation of the University of Groningen. Subsequently, the study design was approved by the local Animal Welfare Body. Procedures complied with the principles of good laboratory animal care following the European Directive 2010/63/EU for the use of animals for scientific purposes. All animals were kept in the same temperature-controlled room (20–22°C, 45–65% humidity, lights on 08.00–20.00 hours) in type 1L (360 cm<sup>2</sup>) polysulfone cages bearing stainless-steel wire covers (UNO BV), with wood shaving bedding, Enviro-dri<sup>®</sup> (TecniLab) and cardboard rolls. All mice were handled by the same researcher. Virgin C57BL/6JOLA-Hsd breeders (34 M, 80 F) 10–12 weeks of age (Envigo) were mated<sup>(16)</sup> in 2–3 F + 1 M groups. Males were removed after 2 d. Pregnancy was confirmed by a >2 g increase in BW after 1 week and occurred in fifty-four females in total. Non-pregnant females were mated again for a maximum of four times. Delivery day was recorded as PN day 0. Pups were randomised between dams, and litters were culled to 4 M + 2 F on PN day 2. Male offspring were weaned at PN day 21 and housed with siblings in pairs. The diets were provided as freshly prepared ‘dough balls’ (40 wt% water, prepared and exchanged daily) from PN days 16 to 42<sup>(16,17)</sup>. This study was not blinded; diets were visually distinct. Breeders and female offspring were euthanised (CO<sub>2</sub>) at weaning and were not further used in this study. From PN42 onwards, mice were fed a LFD (16% energy from fat, D10012G, Research Diets), or a HFD (45% energy from fat, D12451 Research Diets Inc.) and tap water *ad libitum*. Euthanasia was performed between PN days 63 and 70. Online Supplementary Fig. S1 shows a visual representation of the study design.

### Programming diets

Two IMF powders (Nutricia Cuijk B.V.) were used. The IMF powders had a similar macro- and micronutrient content (Table 1);



**Table 1.** Composition of the diets\*  
(Mean values and standard deviations; percentages)

	Control IMF		Experimental IMF		LFD, AIN-93G D10012G		HFD, D12451	
	g	%	g	%	g	%	g	%
Carbohydrate	655	66	655	66	679	68	466	47
Mono/di-saccharides	216	22	214	21	100	10	206	21
Lactose	61.6		69.8					
Sucrose	84.7		84.7		100		206	
Skimmed milk concentrate†	69.6		59.2					
Polysaccharides	381	38	381	38	529	53	202	20
Maltodextrin	101		101		132		117	
Maize starch	280		280		397		84.8	
Fibre	58	6	60	6	50	5	58.3	6
Cellulose	32.0		32.0		50		58.3	
Fructo-oligosaccharides	1.80		1.5					
Galacto-oligosaccharides	24.3		26.3					
Lipids	53	5	60	6	70	7	236	24
Vegetable oil	26.3		26.7		70		29.1	
Anhydrous milk fat	26.8		28.4					
Lard							207	
Milk phospholipids			4.84					
Cholesterol	0.12		0.12				0.20	
Protein	240	24	233	23	203	20	237	24
Whey	67.3		60.5					
Casein	170		170		200		233	
L-Cystine	2.6		2.7		3		3.5	
Mineral mix	35	4	35	4	35	4	58.3	6
E15712 mineral mix	35		35					
S10022G					35			
S10026B							58.3	
Vitamin mix	17	2	17	2	12.5	1	3.5	4
E15712 vitamin mix	10		10					
IMF vitamins and minerals	4.8		5.1					
V10037					10			
V10001C							1.2	
Choline bitartrate	2.2		2.2		2.5		2.3	
Sum	1000	100	1000	100	1000	100	1000	100
Total energy (kcal/g)		3.87		3.87		3.90		4.73
Total energy (kJ/g)		16.2		16.2		16.3		19.8
Particle size	Mean	SD	Mean	SD				
D[4,3] (µm)	0.81	0.2	6.8	0.2	–		–	
D[3,2] (µm)	0.43	0.004	0.86	0.1	–		–	
Surface area (m <sup>2</sup> /g)	15	0.2	7.7	1.0	–		–	

IMF, infant milk formula; LFD, low-fat diet; AIN, American Institute of Nutrition; HFD, high-fat diet; PN, postnatal.

\* Calculated nutrient composition (in g/kg) of the programming diets (PN days 16–42) and the low/high-fat diet (PN days 42–70). The programming diets were created by mixing 71.77% of a fat-free AIN-93 G-compliant diet with 28.23% of IMF powders. The resulting mixture was AIN-93 G compliant, and its lipid fraction was fully derived from IMF lipids.

† Skimmed milk concentrate is an ingredient of the IMF and is primarily composed of lactose and milk protein with minor amounts of milk fat.

both lipid moieties comprised about 50% vegetable oil and 50% milkfat and had a similar fatty acid profile (Table 2). The programming diets were created by mixing 71.77% of a fat-free American Institute of Nutrition (AIN)-93 G-compliant diet with 28.23% of IMF powders. The resulting mixture was AIN-93 G compliant. Diet designs are explained in more detail elsewhere<sup>(9)</sup>. IMF powders (283 g/kg feed) were supplemented with protein and carbohydrate (ssniff-Spezialdiäten GmbH) to obtain AIN-93 G-compliant diets, with a fat moiety (approximately 7 wt%) derived entirely from IMF<sup>(24)</sup>.

### Body composition

Lean and fat mass were quantified by time-domain NMR (LF90II, Bruker Optics) not requiring fasting or anaesthesia, as previously described<sup>(18)</sup>.

### Euthanasia

For reasons of clarity, procedures for euthanasia are described per experiment.

At PN day 21: Unfasted male offspring were anaesthetised (isoflurane/O<sub>2</sub>) (during light phase; at 09.00 hours) and killed by heart puncture to obtain a blood sample.

At PN day 42: Mice were anaesthetised (isoflurane/O<sub>2</sub>) after a 4-h fasting period (during light phase; from 09.00 to 13.00 hours) and killed by heart puncture to obtain a blood sample.

Between PN days 63 and 70:

LFD-plasma: Upon intraperitoneal injection of the LPL inhibitor poloxamer-407 (1 g/kg BW, BASF Corp., in approximately 200 µl sterile PBS solution), fasting mice (midnight to 09.00 hours) were intragastrically administered at  $t = 0$  h a lipid bolus (100 µl) containing 25% olive oil, 75% medium-chain

**Table 2.** Fatty acyl chain composition of the diets\* (Percentages)

	Control IMF	Experimental IMF	LFD, D10012G	HFD, D12451
	%	%	%	%
ΣSaturated + unsaturated	100	100	100	100
ΣSaturated	44	42	17	31
Myristic acid 14:0	8.9	7.1	0.4	1.3
Palmitic acid 16:0	26	25	12	20
Stearic acid 18:0	7.8	8.9	4.1	9.6
Arachidic acid 20:0	0.28	0.32	0.31	0.18
Behenic acid 22:0	0.27	0.39	0.35	0.07
Lignoceric acid 24:0	0.17	0.26	0.14	0.04
Cerotic acid 26:0	0.032	0.039	0.02	–
ΣMonounsaturated	36	39	23	37
Palmitoleic acid 16:1 <i>n</i> -7	1.2	1.1	0.12	1.6
Vaccenic acid 18:1 <i>n</i> -7	1.9	1.9	1.8	2.4
Oleic acid 18:1 <i>n</i> -9	33	35	20	33
Gondoic acid 20:1 <i>n</i> -9	0.38	0.42	0.27	0.55
Erucic acid 22:1 <i>n</i> -9	0.080	0.13	–	–
Nervonic acid 24:1 <i>n</i> -9	0.053	0.074	–	–
ΣPolyunsaturated	20	19	61	32
Σ <i>n</i> -3 species	3.4	3.4	7.0	2.7
α-Linolenic acid 18:3 <i>n</i> -3	2.8	2.8	7.0	2.4
EPA 20:5 <i>n</i> -3	0.12	0.12	–	–
Docosapentaenoic acid 22:5 <i>n</i> -3	0.090	0.099	–	–
DHA 22:6 <i>n</i> -3	0.38	0.38	–	–
Σ <i>n</i> -6 species	16	16	54	29
Linoleic acid 18:2 <i>n</i> -6	16	15	54	28
γ-Linolenic acid 18:3 <i>n</i> -6	0.050	–	–	–
Eicosadienoic acid 20:2 <i>n</i> -6	0.046	–	0.11	0.74
Dihomo-γ-linolenic acid 20:3 <i>n</i> -6	0.091	0.12	–	0.12
Arachidonic acid 20:4 <i>n</i> -6	0.44	0.43	–	0.24
Σ <i>n</i> -6/Σ <i>n</i> -3 ratio	4.8	4.7	7.6	11
Mead acid 20:3 <i>n</i> -9	0.38	0.42	0.06	0.12

IMF, infant milk formula; LFD, low-fat diet; HFD, high-fat diet; PN, postnatal.

\* Fatty acid composition (expressed as the % of total fatty acyl moieties) of the programming diets (PN days 16–42) and the low-/high-fat diet (PN days 42–70), as measured by fatty acyl chain profiling.

TAGS oil, 1 mg triolein-1,1,1-<sup>13</sup>C<sub>3</sub> and 1 mg oleic acid-9,10-<sup>2</sup>H<sub>2</sub>. Blood was drawn at *t* = 0, 1, 2, 3 and 5 h in heparinised haematocrit capillaries (Vitrex).

LFD-organ: Fasting mice (midnight to 09.00 hours) were intragastrically administered at *t* = 0 h a lipid bolus (100 μl) containing 25 % olive oil, 75 % medium-chain TAG oil, 10 mg triolein-1,1,1-<sup>13</sup>C<sub>3</sub> and 1 mg oleic acid-9,10-<sup>2</sup>H<sub>2</sub>. Tissues were collected at *t* = 4 h.

HFD-plasma: Upon intraperitoneal injection of the LPL inhibitor poloxamer-407 (1 g/kg BW in approximately 200 μl sterile PBS), fasting mice (midnight to 09.00 hours) were intragastrically administered at *t* = 0 h a lipid bolus (100 μl) containing 25 % olive oil, 75 % medium-chain TAG oil, 1.7 mg triolein-1,1,1-<sup>13</sup>C<sub>3</sub>, 1 mg oleic acid-9,10-<sup>2</sup>H<sub>2</sub>, 1.9 mg palmitic acid-1,2,3,4-<sup>13</sup>C<sub>4</sub> and 4.9 mg stearic acid-1-<sup>13</sup>C. Blood was drawn at *t* = 0, 1, 2, 3 and 5 h in heparinised haematocrit capillaries.

HFD-organ: Fasting mice (midnight to 09.00 hours) were intragastrically administered at *t* = 0 h a lipid bolus (100 μl) containing 25 % olive oil, 75 % medium-chain TAG oil, 9.4 mg triolein-1,1,1-<sup>13</sup>C<sub>3</sub>, 7.9 mg oleic acid-9,10-<sup>2</sup>H<sub>2</sub>, 2.4 mg palmitic acid U-<sup>13</sup>C<sub>16</sub> and 4.8 mg stearic acid-1-<sup>13</sup>C. Tissues were collected at *t* = 4 h.

At dissection, mice were anaesthetised (isoflurane/O<sub>2</sub>) and killed by heart puncture for collection of a blood sample.

Tissues were snap-frozen in liquid N<sub>2</sub>. Blood samples were spun down at 1300 *g* for 15 min.

Stable isotope-labelled triolein (<sup>13</sup>C) and oleic acid (<sup>2</sup>H) were purchased from Cambridge Isotope Laboratories, Inc. Stable isotope-labelled palmitic acid-1,2,3,4-<sup>13</sup>C<sub>4</sub> and stearic acid were purchased from ISOTEC. Stable isotope-labelled palmitic acid U-<sup>13</sup>C<sub>16</sub> was purchased from CorTecNet.

### Assays

Plasma was analysed using commercially available kits for TAG (Roche; catalogue no. 11877771216), total cholesterol (Roche, catalogue no. 11491458 216), free cholesterol (FC, Spinreact; catalogue no. 41035), NEFA (Sopachem; catalogue no 157819910935) and phospholipids (Sopachem; catalogue no. 157419910930). Esterified cholesterol was calculated as the difference between total and FC.

### Plasma bile acids

Plasma bile acid species were quantified from 25 μl plasma samples using LC-MS, as previously described<sup>(25)</sup>. To 25 μl of plasma, we added a mixture of internal standards (stable isotope-labelled bile acids) in methanol. Samples were centrifuged at 15 800 *g*, and the supernatant was transferred and evaporated at 40°C



under a stream of N<sub>2</sub>. Samples were reconstituted in 200 µl methanol:water (1:1), mixed and centrifuged at 1800 *g* for 3 min. The supernatant was filtered using a 0.2 µm spin filter at 2000 *g* for 10 min. Filtrates were transferred to vials, and 10 µl was injected into the LC-MS/MS system. The system consisted of a Nexera X2 Ultra HPLC system (SHIMADZU) and coupled to a Sciex Qtrap 4500 MD triple quadrupole mass spectrometer (SCIEX). Bile acids were separated with an ACQUITY UPLC BEH C18 Column (1.7 µm × 2.1 × 100 mm) equipped with an ACQUITY UPLC BEH C18 VanGuard Pre-Column (1.7 µm × 2.1 × 5 mm) (Waters). Data were analysed with Analyst MD 1.6.2 software.

### Fatty acyl chain profiling

Cryogenically crushed tissues were homogenised in Potter-Elvehjem tubes in PBS solution. A known quantity of tissue was transferred to glass tubes, capped with silicone-PTFE septum screw caps. Cryogenically crushed adipose tissue was homogenised in Dounce tubes in chloroform:methanol (ratio 2:1), a known quantity of tissue transferred to glass tubes and dried under a stream of N<sub>2</sub> at 45°C. Lipids from a known quantity of plasma, tissue or food were trans-methylated at 90°C for 4 h, liquid-liquid extracted twice using hexane, transferred to a clean tube, dried at 45°C under a stream of N<sub>2</sub>, dissolved in hexane and transferred to GC vials with inserts. Samples were analysed by GC and MS as previously described<sup>(26,27)</sup>. The GC system consisted of 6890N network GC (Agilent Technologies) and was equipped with a HP-ULTRA 1 (50 m length × 0.2 mm diameter, 0.11 µm film thickness, Agilent) column. The GC-MS system consisted of a 7890A GC system coupled to a 5975C mass spectrometer (Agilent) with the same HP-ULTRA 1 column and used an ammonia gas carrier. Oleate methyl ester ammonium ions were monitored at *m/z* 314–318, palmitate methyl ester ions were monitored at *m/z* 288–292 and 303–304 and stearate methyl ester ions were monitored at *m/z* 316–320. Ions were monitored under selected ion recording. The normalised mass isotopomer distributions measured by GC-MS (*m<sub>0</sub>*–*m<sub>x</sub>*) were corrected for natural abundance of <sup>13</sup>C by multiple linear regression, described in more detail elsewhere<sup>(28,29)</sup>.

### Statistical analysis


Group sizes were calculated<sup>(30)</sup> based on an anticipated difference in the slope of fat absorption of 20%, an expected spread of 17.5% for LFD study arms. These data were obtained from previous experiments in our laboratory. HFD feeding is known to introduce additional heterogeneity<sup>(31)</sup>. We chose an expected spread of 20% for HFD study arms with  $\alpha$  0.05 and  $\beta$  0.80. Given these numbers, we required twelve for LFD groups and sixteen for HFD groups. The sizes of groups in the lipid trafficking arm were similarly calculated to be twelve for LFD and sixteen for HFD given the same assumptions. Statistics were performed using SPSS 23 (IBM Corporation). Time series are plotted as medians and interquartile ranges. Single-time data are plotted as Tukey box plots and scatter plots. Analyses were carried out on all mice or samples whenever technically feasible, and material was available. No data were excluded. Data were tested for normality using Q-Q plots. Data which appeared normally distributed were analysed using the two-way ANOVA test,

followed by Bonferroni-corrected simple main effects analyses (one-way ANOVA). Data which did not appear normally distributed were analysed using the Kruskal–Wallis *H* test, followed by the Dunn–Bonferroni *post hoc* test. Fig. 1(a), (b), (f) (FC, cholesteryl ester and NEFA) and Fig. 3 were tested parametrically. The remaining figures were tested using the mentioned non-parametric tests. *P* < 0.05 was considered to indicate statistical significance.

## Results

### Early-life growth and fat mass gain upon low-fat or high-fat diet feeding


BW gain (Fig. 1(a) and (b)), as well as fat and lean mass gain on LFD and HFD (Fig. 1(d) and (e)), was similar when comparing eIMF with cIMF groups for the duration of the study. BW, lean mass and fat mass were similar between all groups at PN day 42. At PN day 56, the diet (LFD *v.* HFD) had a statistically significant effect on the BW (*P* < 0.001). During the period of IMF feeding (until PN day 42), BW were similar between eIMF and cIMF. From PN days 42 until 63, BW were similar between eIMF and cIMF. BW were higher in HFD-fed compared with LFD-fed groups for eIMF and cIMF (both +8%, *P* < 0.001). At PN day 63, the diet had a statistically significant effect on the BW (*P* < 0.001). The IMF did not affect the BW. BW was higher (+15 and +14%, both *P* < 0.001) in HFD *v.* LFD for eIMF and cIMF groups, respectively. There was a difference in the lean and fat mass of the four groups (LFD-cIMF, LFD-eIMF, HFD-cIMF and HFD-eIMF) at PN days 56 and 63 (both *P* < 0.01). Lean and fat mass were not different between eIMF and cIMF at PN days 56 and 63. At PN day 56, when comparing HFD with LFD, lean mass was lower in eIMF (–5%, *P* < 0.01) but similar in cIMF-fed mice. Fat mass was higher in HFD- *v.* LFD-fed mice (+100 and +94%, both *P* < 0.01) for eIMF and cIMF, respectively. At PN day 63, when comparing HFD with LFD, lean mass was lower for eIMF and cIMF (both approximately –6%, *P* < 0.01). Fat mass (+156 and +149%, both *P* < 0.01) was higher in HFD *v.* LFD for eIMF and cIMF, respectively. Daily energy intake at PN day 45 was similar between the four groups (Fig. 1(c)). At PN day 56, daily energy intake was different between groups (*P* = 0.001). Energy intake was higher in HFD-fed *v.* LFD-fed mice, independent of early-life feeding with eIMF or cIMF (+9%, *P* < 0.05, Fig. 1(c)). Plasma lipids were compared between four groups (PN day 21 eIMF and cIMF, and day 42 eIMF and cIMF, Fig. 1(f)). There was a statistically significant difference in plasma TAG (*P* = 0.001) and phospholipids (*P* < 0.001) between these groups. At PN day 21, plasma TAG, cholesterol and phospholipids were similar between eIMF and cIMF. Plasma NEFA tended to be lower in eIMF *v.* cIMF, but this difference was not statistically significant (–19%, *P* = 0.064). At PN day 42, plasma lipids were similar between eIMF and cIMF. Comparing PN days 42–21, plasma TAG were similar in eIMF-fed mice but lower (–51%, *P* < 0.01) in cIMF. FC and cholesteryl ester levels were similar for eIMF- and cIMF-fed mice. Plasma NEFA was lower at PN day 42 compared with day 21 for eIMF (–11%, *P* = 0.002) and cIMF-fed mice (–28%, *P* < 0.001). Plasma phospholipids were lower at PN day 42



**Fig. 1.** Body weight, lean mass and fat mass gain in early life and during low-fat diet (LFD) or high-fat diet (HFD) feeding. Mice were fed either rodent diet made using a control infant milk formula (cIMF) or experimental IMF (eIMF) from postnatal (PN) days 16–42, and either LFD or HFD from PN days 42 to 63–70. Body weight gain on LFD (a) and HFD (b). Lean and fat mass gain on LFD (16% energy from fat; d) and HFD (45% energy from fat; e). Energy intake was calculated from food intake and the manufacturer's provided energy content and shown in kcal/mouse per d for PN day 45 (left) and day 56 (right) (c). Non-fasting plasma lipids at PN day 21 (weaning) and 4 h fasted plasma lipids at PN day 42 (f) and adulthood (PN day 63–70) after LFD or HFD feeding (i). Plasma bile acid species composition in adulthood after LFD (g) and HFD (h). TC, total cholesterol; FC, free cholesterol; CE, cholesteryl esters; Phos, phospholipids; (T) (L) CA, (tauro) (litho) cholic acid; (T) (U/C/H) DCA, (tauro) (urso/cheno/hyo) deoxycholic acid; (T) ( $\alpha/\beta/\omega$ )-MCA, (tauro)- $\alpha/\beta/\omega$ -muricholic acid; n.a., not assessed due to chromatographic issues; U./C., unconjugated/taurine conjugated bile acid species. a–i:  $n \geq 12$ . Values represent medians and interquartile ranges (a and b, d and e –  $\circ$ , cIMF;  $\bullet$ , eIMF) or Tukey box plots and scatter plots (c, f–i –  $\square$ , cIMF;  $\blacksquare$ , eIMF). Error bars are not shown when they fall within the symbol. a and b and d and e contain vertical lines at PN day 16 and 42 to illustrate the change to IMF and LFD or HFD, respectively. Horizontal dotted lines are solely for visual aid. \*  $P < 0.05$ .

compared with day 21 for both eIMF ( $-42\%$ ,  $P < 0.001$ ) and cIMF-fed mice ( $-39\%$ ,  $P < 0.01$ ). In later life (approximately PN day 63), after 4 h of fasting, plasma lipids were similar between IMF groups in LFD- and HFD-fed mice (Fig. 1(i)). Comparing HFD with LFD, plasma TAG levels were similar between HFD and LFD. Plasma total cholesterol (97 and  $+131\%$ , both  $P < 0.001$ ), FC ( $+53$ , and  $+81\%$  both  $P < 0.001$ ) and cholesteryl ester ( $+135$  and  $+173\%$ , both  $P < 0.001$ ) were higher in HFD- *v.* LFD-fed mice in eIMF and cIMF groups, respectively. Plasma NEFA levels were higher in HFD *v.* LFD eIMF-fed mice ( $+27\%$ ,  $P < 0.05$ ) but similar in cIMF mice fed HFD or LFD. Plasma phospholipid levels were similar in eIMF mice fed HFD

or LFD but were higher in HFD *v.* LFD cIMF mice ( $+48\%$ ,  $P < 0.05$ , Fig. 1(i)). The relative composition of the plasma bile acid pool at PN day 63 was compared between the diets and between the IMF. The relative levels of TUDCA ( $P = 0.001$ ), T $\alpha$ -MCA ( $P = 0.039$ ), LCA ( $P = 0.001$ ), TDCA ( $P = 0.001$ ), THDCA ( $P = 0.011$ ) and the fractional sums of the primary and secondary (microbiome-converted) plasma bile acid species ( $P = 0.007$ ) were significantly different between the four groups. Plasma bile acid species were similar between eIMF and cIMF mice in later life (Fig. 1(g) and (h)). Also, plasma bile acid species were comparable between IMF groups in early life (PN days 21 and 42, data not shown). Comparing HFD with LFD at PN day 63,




**Fig. 2.** Plasma concentrations of absorbed fats in mice fed with rodent diet made using a control infant milk formula (cIMF) or experimental IMF (eIMF) in early life and fed a low-fat diet (LFD) or a high-fat diet (HFD) in later life. The plasma concentration of an intragastrically administered stable isotope-labelled TAG (a and b) and NEFA (c–f) is expressed as % of dose/ml plasma. Calculated linear slope for oleate from triolein (g), oleate from oleic acid (h), and palmitate and stearate from palmitic and stearic acid, expressed as % of dose/ml plasma per h. Fats were prevented from being hydrolysed and thus removed from the plasma by using a lipoprotein lipase inhibitor (Poloxamer 407; intraperitoneal 1 g/kg body weight in approximately 200  $\mu$ l sterile PBS). (a–f) –  $\circ$ , cIMF; –  $\bullet$ , eIMF medians and interquartile ranges. (g–i) –  $\square$ , cIMF;  $\blacksquare$ , eIMF Tukey box plots and scatter plots. a and d:  $n$  11–12; b and c, e and f:  $n$  15–16, g and h:  $n$  11–16, i:  $n$  15–16. Error bars are not shown when they fall within the symbol.

it appeared that mice which were fed a HFD had a higher (approximately 2.5-fold higher in HFD *v.* LFD,  $P = 0.011$ ) percentage of secondary bile acids species at the expense of primary bile acid species (Fig. 1(g) and (h)).

#### Rate of fat absorption in mice fed with experimental or control infant milk formula in early life and fed a low- or a high-fat diet in later life

We investigated whether early-life eIMF *v.* cIMF feeding changed the rate of fat absorption in LFD and HFD-fed mice in later life. For this, fasting mice were intraperitoneally administered a LPL inhibitor followed by an intragastrically administered lipid bolus

containing stable isotope ( $^2\text{H}$  or  $^{13}\text{C}$ )-labelled lipid tracers. Plasma concentrations of labelled oleate from administered triolein in LFD-fed mice (Fig. 2(a)) and HFD-fed mice (Fig. 2(b)) were similar between eIMF and cIMF. The calculated slopes of the administered lipids (Fig. 2(g)–(i)) did not show that there was a statistically significant difference between the diet and IMF groups. The calculated slope of plasma oleate M + 1 appearance, representing the rate of triolein absorption was similar between eIMF and cIMF fed LFD: 3.2 (SD 1.8) and 3.9 (SD 2.1) and HFD 2.6 (SD 1.7) and 3.8 (SD 3.0) % dose/ml per h (Fig. 2(g)). Plasma concentrations of administered NEFA in LFD-fed mice (Fig. 2(d)) and HFD-fed mice (Fig. 2(e)) were similar between eIMF and cIMF. The calculated slope of plasma



**Fig. 3.** Tissue concentration of absorbed fats in mice fed with rodent diet made using a control infant milk formula (cIMF) or experimental IMF (eIMF) in early life and fed a low-fat diet (LFD) or a high-fat diet (HFD) in later life. The tissue concentrations of intragastrically administered isotope-labelled TAG (a and b) and NEFA (c–f) are expressed as % of dose/g for tissues or % of dose/ml for plasma. Brain, whole brain homogenate; Epi, epididymal fat pad; Sub, subcutaneous inguinal fat pad; muscle, whole gastrocnemius skeletal muscle homogenate; plasma, heart puncture plasma sample; n.a., not assessed; ND, not detected, below detection limit. a and d:  $n$  12–13; b and c, e and f:  $n$  14–16. Tukey box plots and scatter plots. \*\*  $P < 0.01$ , \*  $P < 0.05$ , †  $P < 0.1$ . (a–f)  cIMF;  eIMF.

oleate M + 2 appearance, representing the rate of free oleic acid absorption, was similar between groups (Fig. 2(h)). Also, plasma concentrations of labelled palmitate (Fig. 2(c)) and stearate (Fig. 2(f)) in HFD-fed mice were similar between eIMF and cIMF. The calculated rate of triolein and free oleic acid absorption appeared similar between HFD- and LFD-fed mice.

#### Tissue concentrations of absorbed fats in mice fed experimental or control infant milk formula in early life and fed a low- or high-fat diet in later life

We determined whether early-life eIMF *v.* cIMF feeding changed later-life postabsorptive trafficking of an identical intragastrically administered lipid bolus after LFD or HFD feeding in later life. For this, mice were intragastrically administered a lipid bolus containing stable isotope-labelled ( $^2\text{H}$  and  $^{13}\text{C}$ ) lipid tracers. Postabsorptive lipid trafficking, that is, to which tissues the administered lipids were trafficked, was assessed by collecting tissues 4 h after intragastrical bolus administration. Data were expressed as a percentage of the administered dose (Fig. 3(a)–(f)). There was a statistically significant interaction between the IMF and the diet for absorbed oleate from triolein in the heart ( $P = 0.025$ ), oleate from triolein in the liver ( $P = 0.004$ ), and for oleate from oleic acid in the heart ( $P = 0.024$ ). The amount of absorbed oleate from triolein in HFD eIMF- *v.* HFD cIMF-fed mice was lower in the heart ( $-44\%$ ,  $P < 0.01$ ), lower in the liver ( $-46\%$ ,  $P < 0.01$ ) and higher in the gastrocnemius muscle ( $+80\%$ ,  $P < 0.05$ ). The amount of absorbed oleate from oleic acid in HFD eIMF- *v.* HFD cIMF-

fed mice was lower in the heart ( $-49\%$ ,  $P = 0.03$ ), lower in the liver ( $-49\%$ ,  $P = 0.02$ ) and lower in the gastrocnemius muscle ( $-71\%$ ,  $P = 0.004$ ). The concentration of palmitate from palmitic acid in HFD eIMF- *v.* HFD cIMF-fed mice was lower in heart tissue ( $-40\%$ ,  $P = 0.038$ ), liver tissue ( $-44\%$ ,  $P = 0.004$ ), but similar in muscle tissue and plasma. The concentration of stearate from stearic acid in HFD eIMF- *v.* HFD cIMF-fed mice tended to be lower in heart tissue ( $-39\%$ ,  $P = 0.058$ ), but this comparison was not statistically significant. Stearate from stearic acid had a lower concentration in HFD eIMF- *v.* HFD cIMF-fed mice in liver tissue ( $-44\%$ ,  $P = 0.011$ ) and muscle tissue ( $-67\%$ ,  $P = 0.007$ ). When comparing HFD with LFD, the amount of absorbed oleate from triolein was higher in the heart ( $+107$  and  $+396\%$   $P < 0.001$  and  $P < 0.05$ ) for eIMF- and cIMF-fed mice, respectively. The amount of oleate from triolein in the liver between HFD and LFD was lower ( $-48\%$ ,  $P < 0.01$ ) in HFD *v.* LFD eIMF-fed mice but similar in HFD and LFD cIMF-fed mice. The amount of oleate from triolein in the gastrocnemius muscle was similar between HFD and LFD in cIMF- and eIMF-fed mice. The amount of absorbed oleate from oleic acid was similar between HFD and LFD eIMF-fed mice, but higher ( $+325\%$ ,  $P < 0.001$ ) in HFD *v.* LFD cIMF-fed mice. When comparing HFD with LFD, the amount of oleate from oleic acid in the liver was lower in eIMF ( $-71\%$ ,  $P < 0.001$ ) and cIMF ( $-47\%$ ,  $P < 0.001$ )-fed mice. The concentration of administered lipids in whole brain and adipose depots (epididymal adipose depot and inguinal adipose depot) was very close to or below the limit of detection. Correction for tissue protein content did not statistically change the aforementioned comparisons (data not shown).

## Discussion

In this study, we tested the hypothesis that eIMF *v.* cIMF programmes the uptake rate and/or postabsorptive trafficking of lipids in later life. It was anticipated that adiposity and/or HFD-feeding affects the uptake rate and the storage of absorbed lipids<sup>(21,23)</sup>. Therefore, our study was designed to test the hypothesis in LFD and HFD conditions prior to the expected time point at which eIMF- and cIMF-programmed mice started to diverge in their adiposity<sup>(18)</sup>. In previous works, we observed that the adiposity started to diverge at approximately PN day 70, that is, 28 d after commencing a HFD<sup>(18)</sup>. We showed (Fig. 1) that the adiposity was similar between eIMF and cIMF mice at the time point at which we measured lipid absorption rates and lipid trafficking. We verified that bile acid composition, which can be a critical determinant for lipid absorption efficiency<sup>(32)</sup>, was similar between IMF groups. As adiposity and bile acid composition are similar between eIMF and cIMF, they are unlikely to be a strong determinant for lipid absorption rate or lipid trafficking. The results in our model indicate that the rate of fat absorption in later life is not affected by early-life eIMF feeding (Fig. 2). However, our data do demonstrate that postabsorptive lipid trafficking is a trait that is modifiable by early-life feeding with eIMF (Fig. 3). It is tempting to speculate that these postabsorptive differences, which are only apparent under challenging (HFD feeding) conditions, are related to the previously observed long-term difference in BW and fat mass gain<sup>(18)</sup>.

In humans, the rate of fat absorption determines, to some extent, the 'fate' of dietary fat, that is, storage or oxidation, especially in obese subjects<sup>(21)</sup>. Fats which are rapidly absorbed are oxidised faster compared with fats which are less rapidly absorbed<sup>(21)</sup>. This parameter is coined 'lipid partitioning'. It is currently not known whether the rate of fat absorption affects the 'destination' of dietary fat, that is, to which tissue (such as the heart, or the liver) it is transported. We refer to this parameter as 'lipid trafficking'. Our data indicate that the postabsorptive differences between IMF groups (under challenging HFD conditions) are likely not related to the rate of fat absorption, as plasma concentrations of absorbed fats were similar between IMF groups (Figs. 2 and 3).

It is known, at least in rats, that metabolically active tissues such as the heart, skeletal muscle and adipose tissue increase their fatty acid uptake with body adiposity<sup>(33)</sup>. The heart, skeletal muscle and adipose tissue of obese rats display a higher fatty acid uptake rate compared with lean littermates<sup>(33)</sup>. HFD *v.* LFD feeding lowers the non-fasting RER, a calculated measure obtained by dividing the exhaled quantity of CO<sub>2</sub> by the exhaled quantity of O<sub>2</sub><sup>(34)</sup>. The RER can be used to estimate the whole-body contribution of fatty acid oxidation to the total energy production as fatty acid oxidation typically requires more atmospheric oxygen per exhaled carbon dioxide volume, thereby lowering the RER<sup>(34)</sup>. These indirect calorimetry data illustrate that fatty acid oxidation is increased by switching from LFD to HFD, which logically implies that fatty acid transport towards metabolically active tissues must also be increased. Indeed, insulin-stimulated fatty acid oxidation in the heart is >4-fold higher in HFD-fed obese mice *v.* LFD-fed lean mice<sup>(35)</sup>, which mandates a (much) higher cardiac fatty acid uptake rate.

Therefore, we consider our HFD *v.* LFD lipid trafficking findings to be in line with expectations and with literature.

The postabsorptive differences in concentrations of administered lipids in tissue may be caused by tissue-specific differences in LPL activity. LPL is the rate-limiting step in tissue uptake of plasma TAG and is present in the vascular bed of extrahepatic tissues including the heart, skeletal muscle and adipose tissue<sup>(36,37)</sup>. LPL is regulated at transcriptional and post-translational level<sup>(37,38)</sup>. LPL has a higher binding affinity and activity for larger lipoprotein particles compared with smaller lipoprotein particles<sup>(36,39)</sup>. The difference in LPL's binding affinity for small and large lipoprotein particles is not well understood and appears counterintuitive considering that surface area is usually correlated positively, and not negatively, with enzyme activity. The apparent negative correlation between LPL binding affinity and lipoprotein surface area may, however, contribute to the ability of LPL to rapidly respond to large (postprandial) variations in plasma TAG levels<sup>(21)</sup>. Absorption of large amounts of fat typically results in larger CM<sup>(6,21)</sup>. LPL hydrolyses TAG from lipoprotein particles (including CM) resulting in NEFA. Plasma NEFA are taken up by tissues via active saturable processes (CD36) and by passive non-saturable processes (non-CD36)<sup>(36)</sup>. The hydrolysis of CM-TAG eventually leads to the formation of CM remnants. CM remnants penetrate the liver sinusoidal endothelial fenestrations, bind to hepatocytes and are taken up and cleared from the plasma<sup>(40)</sup>.

Considering the aforementioned modifiers of LPL activity, the differences in postabsorptive lipid trafficking between HFD-fed IMF groups may be due to differences in the amount of LPL protein in the various extrahepatic vascular beds *per se*, and/or differences in CM diameter. It is known that LPL activity is higher in adipose tissue of obese than in that of lean human subjects<sup>(23)</sup>. Weight loss in obese subjects induces an increase in adipose tissue LPL activity, which returns to baseline activity levels upon rebound weight gain<sup>(23)</sup>. To some extent, LPL protein levels are regulated via epigenetic means by DNA methylation of the LPL promoter region<sup>(37)</sup>. The degree of LPL promoter methylation positively associates with abnormalities of the metabolic profile and basal and postprandial TAG<sup>(37)</sup>. It is not known whether a relationship exists between LPL activity and whole-body energy balance *per se*. Though, a higher rate of lipid absorption, leading to a greater CM diameter, does result in a more rapid development of the sensation of hunger in obese human subjects and vice versa<sup>(21)</sup>. This observation suggests that either LPL activity, the rate of plasma lipid disappearance and/or the rate of tissue lipid appearance may be related to the sensation of hunger<sup>(21)</sup>. It is still unclear what is the cause and effect. However, if LPL activity does contribute to the sensation of hunger, then this would be an interesting parameter to explore in the context of obesity. The specific link between early-life nutrition and later-life LPL activity, if any, would be an interesting avenue to further explore in a future study.

Circulating fats enter the liver mostly via LPL-independent routes, namely via the uptake of CM remnants<sup>(40)</sup>. We noted that, at the time of sampling, plasma levels of labelled fats were similar between HFD-fed IMF groups. It could be that labelled fats were still being absorbed from the gut, replenishing the plasma pool. Therefore, the observed lower concentrations of absorbed fats in



the livers of eIMF-primed HFD-fed mice suggest that CM remnants contained less labelled TAG at the time of hepatic uptake<sup>(40)</sup>. If this were true, it would indicate that extrahepatic tissues are more extensively hydrolysing CM-TAG in eIMF *v.* cIMF mice<sup>(36)</sup>.

In the interpretation of our tissue data (Fig. 3), we assume that differences in tissue levels of administered fats are mostly due to differences in tissue uptake of plasma fats. Alternatively, the effects may be related to differences in  $\beta$ -oxidation rates between the two groups. Within the 4 h time frame, approximately 5% of the total administered palmitate, stearate and oleate can be expected to be oxidised and thus removed from the measurable pools<sup>(41)</sup>. Previously, it was noted that, upon a Western-style diet challenge, gene expression and protein levels of mitochondrial oxidative capacity markers were higher in skeletal muscle and adipose tissue in eIMF compared with cIMF-fed mice<sup>(42)</sup>. These observations could indicate that part of the differences in measured labelled fats, at least in skeletal muscle tissue, is due to  $\beta$ -oxidation. However, given the magnitude of the differences in labelled fats (Fig. 3), we assume that the majority of the differences are due to differences in lipid trafficking, and only partially due to  $\beta$ -oxidation.

This study was part of a series of experiments designed to test an eIMF with a lipid structure more similar to human milk<sup>(9,15–18,42)</sup>. For bringing the eIMF to market, its safety and tolerance (in infants) must be evaluated. A recently completed trial (Dutch trial register NTR3683) and its accompanying paper found and reported that the eIMF was safe and well tolerated<sup>(43)</sup>. That is, the number or severity of adverse events was similar between eIMF and a commercially available cIMF<sup>(43)</sup>. In healthy term infants, early-life growth (i.e. daily weight gain) was equivalent between eIMF and the cIMF<sup>(43)</sup>. Follow-up (5 years) of infants fed eIMF in early life (Dutch Trial Register NTR5538) is expected to provide insights into BMI, and the prevalence of overweight and obesity at 3, 4 and 5 years of age. The results obtained in the present study suggest that eIMF programming may be especially relevant for groups at risk of becoming overweight in young adult life<sup>(18)</sup>. Previously, we demonstrated that the effects of this early diet (eIMF *v.* cIMF) in our model were transient and tended to disappear after approximately PN day 130 (after 12 weeks of HFD feeding)<sup>(18)</sup>. It is not clear whether the transiency of the effect is caused by the duration of the exposure to the challenging diet or by the accumulated total BW or fat mass.

### Conclusion

The present study shows that when mice are fed with eIMF or cIMF in early life and fed a LFD or HFD in later life, the rate of fat absorption, upon intragastric administration of an identical lipid bolus, is similar between IMF groups. Thus, the rate of fat absorption in later life does not seem to be affected by an early-life diet containing large phospholipid-coated lipid globules (eIMF). Instead, postabsorptive lipid trafficking may, in a challenging (HFD-fed) environment, be modifiable by early-life feeding with eIMF. It is tempting to speculate that changes in postabsorptive trafficking are related to the observed effects

on later-life BW and fat mass gain upon a persistent long-term obesogenic challenge.

### Acknowledgements

We thank Renze Boverhof, Matilda Arvidsson Kvissberg, Mirjam Lohuis, Rima Mistry, Fan Liu, Michelle Brad, Dilys Eikelboom (Department of Pediatrics, University Medical Center Groningen) and Violeta Stojanovska (Department of Obstetrics, University Medical Center Groningen) for technical and analytical assistance.

Support for this study has been obtained from Danone Nutricia Research. The funder contributed to the study design and the preparation of the manuscript. The funder did not contribute to the conduct of the study, analysis of samples or data and interpretation of findings.

B. J. M. H., H. J. V. and O. A. H. O. R. formulated the research question and designed the study. R. H., A. J. and O. A. H. O. R. carried out the study. I. A. M., A. J., V. W. B., T. H. D., M. K. and O. A. H. O. R. analysed the data. H. J. V., F. K., E. M. B., B. J. M. H. and O. A. H. O. R. wrote the paper.

B. J. M. H. and E. M. B. are employed by Danone Nutricia Research. H. J. V. was a consultant for Danone Nutricia Research outside the submitted work, for which his institution was compensated financially. Other authors have no known conflicts of interest.

### Supplementary material

For supplementary material referred to in this article, please visit <https://doi.org/10.1017/S0007114520002421>

### References

1. Arenz S, Ruckerl R, Koletzko B, *et al.* (2004) Breast-feeding and childhood obesity – a systematic review. *Int J Obes Relat Metab Disord* **28**, 1247–1256.
2. Gillman MW, Rifas-Shiman SL, Camargo CA, *et al.* (2001) Risk of overweight among adolescents who were breastfed as infants. *J Am Med Assoc* **285**, 2461–2467.
3. Koletzko B, von Kries R, Monasterolo RC, *et al.* (2009) Can infant feeding choices modulate later obesity risk? *Am J Clin Nutr* **89**, 1502S–1508S.
4. Dewey KG (2003) Is breastfeeding protective against child obesity? *J Hum Lact* **19**, 9–18.
5. Lucas A (1991) Programming by early nutrition in man. *Ciba Found Symp* **156**, 38–50.
6. Teller IC, Schoen S, van de Heijning B, *et al.* (2017) Differences in postprandial lipid response to breast- or formula-feeding in 8-week-old infants. *J Pediatr Gastroenterol Nutr* **64**, 616–623.
7. Bourlieu C & Michalski MC (2015) Structure-function relationship of the milk fat globule. *Curr Opin Clin Nutr Metab Care* **18**, 118–127.
8. Andreas NJ, Kampmann B, Mehring Le-Doare K (2015) Human breast milk: a review on its composition and bioactivity. *Early Hum Dev* **91**, 629–635.
9. Gallier S, Vocking K, Post JA, *et al.* (2015) A novel infant milk formula concept: mimicking the human milk fat globule structure. *Colloids Surf B Biointerfaces* **136**, 329–339.



10. Patton S & Keenan TW (1975) The milk fat globule membrane. *Biochim Biophys Acta* **415**, 273–309.
11. Werner A, Havinga R, Perton F, *et al.* (2006) Lymphatic chylomicron size is inversely related to biliary phospholipid secretion in mice. *Am J Physiol Gastrointest Liver Physiol* **290** G1177–G1185.
12. Martins I, Mortimer B, Miller J, *et al.* (1996) Effects of particle size and number on the plasma clearance of chylomicrons and remnants. *J Lipid Res* **37**, 2696–2705.
13. Ahern GJ, Hennessy AA, Ryan CA, *et al.* (2019) Advances in infant formula science. *Annu Rev Food Sci Technol* **10**, 75–102.
14. Michalski MC, Briard V, Michel F, *et al.* (2005) Size distribution of fat globules in human colostrum, breast milk, and infant formula. *J Dairy Sci* **88**, 1927–1940.
15. Baars A, Oosting A, Engels E, *et al.* (2016) Milk fat globule membrane coating of large lipid droplets in the diet of young mice prevents body fat accumulation in adulthood. *Br J Nutr* **115**, 1930–1937.
16. Oosting A, Kegler D, Wopereis HJ, *et al.* (2012) Size and phospholipid coating of lipid droplets in the diet of young mice modify body fat accumulation in adulthood. *Pediatr Res* **72**, 362–369.
17. Oosting A, van Vlies N, Kegler D, *et al.* (2014) Effect of dietary lipid structure in early postnatal life on mouse adipose tissue development and function in adulthood. *Br J Nutr* **111**, 215–226.
18. Ronda OAHO, van de Heijning BJM, de Bruin A, *et al.* (2019) Programming effects of an early life diet containing large phospholipid-coated lipid globules are transient under continuous exposure to a high-fat diet. *Br J Nutr* **122**, 1321–1328.
19. Schipper L, Abrahamse M, Kegler D, *et al.* (2010) 1065 Adult body fat accumulation is not affected by adding phospholipid ingredient and only marginally by lipid-droplet size in the post-natal diet. *Pediatr Res* **68**, 529.
20. Vurma M, DeMichele S & Tso P (2018) Comparison of fat absorption mechanisms *in vivo* between human milk and infant formula containing novel absorption enhancement technology. *J Pediatr Gastroenterol Nutr* **66**, 1096.
21. Vors C, Pineau G, Gabert L, *et al.* (2013) Modulating absorption and postprandial handling of dietary fatty acids by structuring fat in the meal: a randomized crossover clinical trial. *Am J Clin Nutr* **97**, 23–36.
22. Naito M & Wisse E (1978) Filtration effect of endothelial fenestrations on chylomicron transport in neonatal rat liver sinusoids. *Cell Tissue Res* **190**, 371–382.
23. Schwartz RS & Brunzell JD (1981) Increase of adipose tissue lipoprotein lipase activity with weight loss. *J Clin Invest* **67**, 1425–1430.
24. Reeves PG, Nielsen FH & Fahey GC Jr (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition *ad hoc* writing committee on the reformulation of the AIN-76A rodent diet. *J Nutr* **123**, 1939–1951.
25. Nagy RA, van Montfoort AP, Dijkers A, *et al.* (2015) Presence of bile acids in human follicular fluid and their relation with embryo development in modified natural cycle IVF. *Hum Reprod* **30**, 1102–1109.
26. Verkade HJ, Hoving EB, Muskiet FA, *et al.* (1991) Fat absorption in neonates: comparison of long-chain-fatty-acid and triglyceride compositions of formula, feces, and blood. *Am J Clin Nutr* **53**, 643–651.
27. Bandsma RHJ, Wiegman CH, Herling AW, *et al.* (2001) Acute inhibition of glucose-6-phosphate translocator activity leads to increased *de novo* lipogenesis and development of hepatic steatosis without affecting VLDL production in rats. *Diabetes* **50**, 2591–2597.
28. Lee WNP, Byerley LO, Bergner EA, *et al.* (1991) Mass isotopomer analysis: theoretical and practical considerations. *Biol Mass Spectrom* **20**, 451–458.
29. Ronda OAHO, van Dijk TH, Verkade HJ, *et al.* (2016) Measurement of intestinal and peripheral cholesterol fluxes by a dual-tracer balance method. In *Current Protocols in Mouse Biology*, pp. 408–434 [R Arkell, S Brown, Y Herculat, M Justice and C Lutz, editors]. Hoboken, NJ: John Wiley & Sons, Inc.
30. Rosner B (2015) *Fundamentals of Biostatistics*. Toronto: Nelson Education.
31. Burcelin R, Crivelli V, Dacosta A, *et al.* (2002) Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. *Am J Physiol Endocrinol Metab* **282** E834–E842.
32. Hofmann AF (1999) Bile acids: the good, the bad, and the ugly. *Physiology* **14**, 24–29.
33. Luiken JJFP, Arumugam Y, Dyck DJ, *et al.* (2001) Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. *J Biol Chem* **276**, 40567–40573.
34. Marvyn PM, Bradley RM, Mardian EB, *et al.* (2016) Data on oxygen consumption rate, respiratory exchange ratio, and movement in C57BL/6J female mice on the third day of consuming a high-fat diet. *Data Brief* **7**, 472–475.
35. Shearer J, Fueger PT, Wang Z, *et al.* (2008) Metabolic implications of reduced heart-type fatty acid binding protein in insulin resistant cardiac muscle. *Biochim Biophys Acta* **1782**, 586–592.
36. Bharadwaj KG, Hiyama Y, Hu Y, *et al.* (2010) Chylomicron- and VLDL-derived lipids enter the heart through different pathways: *in vivo* evidence for receptor- and non-receptor-mediated fatty acid uptake. *J Biol Chem* **285**, 37976–37986.
37. Castellano-Castillo D, Moreno-Indias I, Fernandez-Garcia JC, *et al.* (2018) Adipose tissue LPL methylation is associated with triglyceride concentrations in the metabolic syndrome. *Clin Chem* **64**, 210–218.
38. Kersten S (2014) Physiological regulation of lipoprotein lipase. *Biochim Biophys Acta* **1841**, 919–933.
39. Xiang S-Q, Cianflone K, Kalant D, *et al.* (1999) Differential binding of triglyceride-rich lipoproteins to lipoprotein lipase. *J Lipid Res* **40**, 1655–1662.
40. Crawford SE & Borensztajn J (1999) Plasma clearance and liver uptake of chylomicron remnants generated by hepatic lipase lipolysis: evidence for a lactoferrin-sensitive and apolipoprotein E-independent pathway. *J Lipid Res* **40**, 797–805.
41. DeLany JP, Windhauser MM, Champagne CM, *et al.* (2000) Differential oxidation of individual dietary fatty acids in humans. *Am J Clin Nutr* **72**, 905–911.
42. Kodde A, van der Beek EM, Phielix E, *et al.* (2017) Supramolecular structure of dietary fat in early life modulates expression of markers for mitochondrial content and capacity in adipose tissue of adult mice. *Nutr Metab* **14**, 37.
43. Breij LM, Abrahamse-Berkeveld M, Vandenplas Y, *et al.* (2019) An infant formula with large, milk phospholipid-coated lipid droplets containing a mixture of dairy and vegetable lipids supports adequate growth and is well tolerated in healthy, term infants. *Am J Clin Nutr* **109**, 586–596.